KRAS and non-small cell lung carcinoma: By contrast, when taking into account all the K-Ras mutations detected by the three techniques, our results failed to confirm K-Ras oncogenic activation as a significant marker of poor prognosis after surgery for NSCLC (median EFS 16 months vs 47 months, HR=1.19, CI 95%: 0.61–2.32, NS) (Figure 4).